Back to search results

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Renal Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope, Irvine, California, United States

    Contact: Study coordinator (Charles Nguyen, MD) · charnguyen@coh.org
    Contact: Principal Investigator (Charles Nguyen, MD)

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Jacob Zaemes, MD) · jzaemes@bidmc.harvard.edu

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Bradley McGregor, MD) · bradley_mcgregor@dfci.harvard.edu

  • University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Irene Tsung, MD) · itsung@med.umich.edu

  • UT Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Hans Hammers, M.D., Ph.D.) · hans.hammers@utsouthwestern.edu

  • M D Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Eric Jonasch, M D) · ejonasch@mdanderson.org · 713-563-7232
    Contact: Principal Investigator (Eric Jonasch, M D)
Study leads

  • Eric Jonasch, M D

    Principal Investigator

    M.D. Anderson Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)